NBIXNMSHealthcare·Drug Manufacturers - Specialty & Generic#8 in industry

Neurocrine Biosciences, Inc.

Reports in 9d· 2026-05-05

-5.1% · 90d

$127.04

-0.68 (-0.53%)

News

No News Yet

Press releases and SEC filings for NBIX will appear here as they are published.

Check back later for updates

Key Data

Market Cap$12.78B

Open$127.43

Prev Close$127.72

Day Range$126.99 – $129.40

52W Range$104.73 – $160.18

Volume569,489

P/E (TTM)27.20

EPS$4.67

Dividend Yield—

Beta0.35

Profit Margin16.73%

Revenue Growth28.30%

Price Target$185.65(+46.1%)

Next Earnings2026-05-05(9d)

Analyst Ratings

Strong Buy27 analysts

Buy 23Hold 4Sell 0

About

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Healthcare · Drug Manufacturers - Specialty & Generic

2,000 employees

www.neurocrine.com